Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb – Research Grade

Description of Nelistotug Biosimilar - Anti-Cell surface antigen CD96 mAb - Research Grade

Introduction

Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb – Research Grade is a monoclonal antibody (mAb) that specifically targets the cell surface antigen CD96. This biosimilar is a highly effective and safe therapeutic option for various diseases and has been extensively researched and developed by Nelistotug Biosimilar.

Structure of Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb

Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, and has a molecular weight of approximately 150 kDa. The antibody has a unique binding site that specifically recognizes and binds to the cell surface antigen CD96.

Activity of Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb

The main activity of Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb is to block the function of CD96, a cell surface glycoprotein that is expressed on various immune cells. CD96 is known to play a crucial role in regulating immune responses, and its dysregulation has been linked to various diseases such as cancer, autoimmune disorders, and infectious diseases. By binding to CD96, Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb inhibits its activity and modulates the immune response.

Application of Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb

1. Treatment of cancer Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb has shown promising results in the treatment of various types of cancer. CD96 is overexpressed on tumor cells and has been linked to tumor growth and metastasis. By targeting CD96, Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb can inhibit tumor growth and enhance the effectiveness of other cancer therapies.

2.

Autoimmune disorders

CD96 has also been implicated in the pathogenesis of autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb can modulate the immune response and potentially alleviate the symptoms of these diseases.

3.

Infectious diseases

CD96 has been found to play a role in the immune response against various infectious agents. Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb can enhance the immune response and aid in the clearance of these pathogens.

4. Research tool Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb is also a valuable research tool for studying the function of CD96 and its role in various diseases. Its high specificity and potency make it a reliable tool for studying the immune response and developing new therapies.

Conclusion

Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb is a highly effective and safe therapeutic option for various diseases. Its unique structure and mechanism of action make it a valuable addition to the treatment options for cancer, autoimmune disorders, and infectious diseases. Additionally, it is a valuable research tool for studying the immune response and developing new therapies. With ongoing research and development, Nelistotug Biosimilar – Anti-Cell surface antigen CD96 mAb has the potential to improve the lives of patients and contribute to advancements in the field of immunotherapy.